{"id":373826,"date":"2023-12-08T05:23:21","date_gmt":"2023-12-08T10:23:21","guid":{"rendered":"https:\/\/platohealth.ai\/abbvie-to-buy-neuroscience-specialist-cerevel-therapeutics\/"},"modified":"2023-12-09T11:25:40","modified_gmt":"2023-12-09T16:25:40","slug":"abbvie-to-buy-neuroscience-specialist-cerevel-therapeutics","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/abbvie-to-buy-neuroscience-specialist-cerevel-therapeutics\/","title":{"rendered":"AbbVie to buy neuroscience specialist Cerevel Therapeutics","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
\n

AbbVie plans to acquire neuroscience specialist Cerevel Therapeutics for $45 per share, or around $8.7 billion.<\/p>\n<\/div>\n

\n\"AbbVie\"AbbVie<\/div>\n

AbbVie has signed a definitive agreement to acquire Cerevel Therapeutics and its neuroscience pipeline \u2013 including antipsychotic emraclidine \u2013 for approximately $8.7 billion.<\/p>\n

Cerevel\u2019s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson\u2019s disease, and mood disorders.<\/p>\n

AbbVie said the acquisition complements its neuroscience portfolio, adding a range of assets with potential across psychiatric and neurological disorders with unmet need.<\/p>\n

\u201cOur existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade,\u201d commented Richard A. Gonzalez, chairman and chief executive officer of AbbVie.<\/p>\n

Cerevel\u2019s neuroscience assets in clinical development\u00a0<\/h2>\n

As part of the deal AbbVie will acquire antipsychotic emraclidine, which is currently in Phase II trials<\/a> for schizophrenia and has potential in dementia-related psychosis in Alzheimer\u2019s and Parkinson\u2019s diseases.<\/p>\n

Emraclidine is a positive allosteric modulator (PAM) of the muscarinic M4 receptor. The drug has shown promising efficacy and safety in a Phase Ib study for schizophrenia. A Phase I study of emraclidine is also underway in in elderly healthy volunteers in support of a potential Alzheimer\u2019s disease psychosis programme.<\/p>\n

Cerevel\u2019s other neuroscience assets in clinical development include:<\/p>\n